Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P850064/S056

LifePulse High Frequency Ventilator

Bunnell, Inc. · Decision date Sep 28, 2026

MEDTECHLEDGER EXPLANATIONP850064/S056

What did the FDA approve?

The FDA's Center for Devices and Radiological Health completed review of a premarket approval application 180-day supplement for the LifePulse High Frequency Ventilator, product code LSZ, submitted by Bunnell, Inc. The supplement is logged under P850064/S056, and its stated reason is a labeling change covering indications, instructions, shelf life or tradename; the decision recorded is approval. The action concerns the device's Indications for Use, not a new approval of the whole system.

The approved updated IFU reads that the device is indicated for treating pediatric patients, including neonates, who require temporary ventilatory support for acute respiratory failure. The statement also assigns the clinician responsibility for determining appropriate use and for considering the patient's respiratory status and general health when setting ventilator settings. The database entry does not describe the prior IFU wording, the basis for the change, or any clinical data, so the degree of change from the earlier labeling remains unspecified.

FDA approval order statement

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) 180-day supplement, which requested approval for an update to the Indications for Use (IFU). The approved updated IFU will read: The LifePulse High Frequency Ventilator is indicated for treating pediatric patients (including neonates) who require temporary ventilatory support for acute respiratory failure. It is the responsibility of the clinician to determine the appropriate use of the LifePulse High Frequency Ventilator. The user needs to consider the respiratory status and the general state of health of the patient in order to optimally set ventilator settings for the patients condition(s).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Anesthesiology
Decision date
Sep 28, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P850064/S056
Regulatory pathway
PMA supplement
Applicant
Bunnell, Inc.
Product code
LSZ
Decision code
APPR
Decision date
Sep 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: VENTILATOR, HIGH FREQUENCY.

Applicant
Bunnell, Inc.
Product code
LSZ
FDA device class
3

For the original device and its historical approval scope, see PMA P850064. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P850064 · Original PMA

    MODEL 203 LIFE PULSE HIGH FREQUENCY VENTILATOR

  2. P850064/S056 received

    Application receipt date recorded by FDA.

  3. P850064/S056 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P850064. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P850064

Product / regulatory recordCompanyPathwayDecision dateSource
Bunnell, Inc.PMA approvalJun 30, 1988FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bunnell, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
436 Lawndale Dr., Salt Lake City, UT, 84115

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records